iMIX

What iMIX does

iMIX is a privately-held New Zealand pharmaceutical compounder headquartered in Napier, Hawke's Bay. The company operates a purpose-built, Medsafe-licensed Good Manufacturing Practice (GMP) facility commissioned in 2019, through which it is authorised to manufacture medicines for the New Zealand market. iMIX is led by founder Jeremy Egerton and operates with a headcount in the 1-10 range.

The company's product portfolio consists of three core service lines: Cytotoxic Compounding (specialised chemotherapy and immunotherapy preparations using non-PVC IV bags), CIVAS (Centralised Intravenous Additives Service), and general Aseptic Compounding. These services are delivered from the single Hawke's Bay facility to public and private healthcare providers throughout New Zealand. The underlying technology is conventional sterile pharmaceutical manufacturing with GMP-compliant quality systems; no proprietary software or AI/ML components are disclosed.

iMIX runs a direct, sales-led B2B go-to-market targeting enterprise healthcare buyers — primarily New Zealand district health boards and private hospital networks. Pricing is quote-based and tailored to individual patient and client requirements, with no public pricing or standard rate cards disclosed. Revenue is generated through professional service fees for compounded preparations rather than licensing, subscriptions, or product sales. Marketing is conducted principally through the company website (imix.nz) and direct client engagement, supported by a dedicated client portal (products.imix.nz) for order management. The company is fully founder-controlled with no disclosed institutional investors beyond a 2019 Callaghan Innovation grant of approximately NZD 56,000.

Name

iMIX

Legal name

iMIX

Website

https://imix.nz

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

iMIX is a New Zealand GMP-licensed aseptic compounder in Napier providing cytotoxic, CIVAS, and sterile compounding services to public and private healthcare providers nationwide, specialising in patient-specific chemotherapy and immunotherapy preparations.

Ownership category

akta.pro rank

Product category

Pharmaceutical Compounding Services

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

akta.pro secondary industry

Compounding & Customized Medication Management Support (HSABALAL)

Keywords

• Aseptic compounding services
• Cytotoxic compounding
• CIVAS services
• Pharmaceutical compounding
• Personalised medicines

Headquarters

HQ city

Napier

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D

Revenue model

1. Compounding Services: iMIX generates revenue through providing specialised aseptic compounding services including Cytotoxic, CIVAS, and general Aseptic Compounding to healthcare providers. Services are tailored to individual patient needs and delivered through a collaborative model with healthcare professionals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

iMIX operates a purpose-built, Medsafe GMP-licensed pharmaceutical compounding facility in Hawke's Bay, New Zealand, delivering personalised aseptic, cytotoxic (chemotherapy/immunotherapy), and CIVAS (Centralised Intravenous Additives) compounding services to public and private healthcare providers throughout New Zealand. The company specialises in highly customised, patient-specific compounded medicines for niche or technically challenging clinical needs.

Product overview

iMIX offers a unified personalised health platform built around GMP Licensed Aseptic Compounding services. The company's product portfolio consists of three interconnected core offerings: Aseptic Compounding, Cytotoxic Compounding, and CIVAS (Centralised Intravenous Additives Service). These services work together to provide health professionals with quality, tailored treatments and therapies that can be customised for individual patient needs. iMIX delivers a responsive, personal, and innovative service from their purpose-built GMP facility in Hawke's Bay, New Zealand, serving both public and private healthcare providers throughout the country.

Differentiator

Problem solved

Functional benefit

Products and services

• Aseptic Compounding GMP-licensed aseptic compounding service enabling health professionals to provide quality, customised treatments to patients, with high levels of personalisation and customisation for niche or technically challenging patient needs.
• Cytotoxic Compounding Specialised chemotherapy and immunotherapy compounding service for both public and private healthcare providers, delivered using non-PVC IV bags to ensure highest quality consumables.
• CIVAS (Centralised Intravenous Additives Service) Sector-wide leading-edge innovative Centralised Intravenous Additives Service with extensive international experience, delivering cost-effective and efficient compounding throughout New Zealand via advanced systems and processes.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Baxter International: Baxter manufactures IV solutions, injectable pharmaceuticals, and provides compounding-adjacent pharmacy services globally. Relevant broad incumbent to iMIX given overlap in sterile injectable manufacturing and hospital pharmacy supply.
• B. Braun: B. Braun is a global medical device and pharmaceutical services company offering IV solutions, infusion therapy, and compounding-related products. Comparable to iMIX in the broader IV admixture and sterile compounding space, though it operates at much greater scale and across multiple product categories.
• ICU Medical: ICU Medical provides IV therapy, infusion systems, and closed-system transfer devices used in compounding and administration of hazardous drugs. Adjacent comparable to iMIX in cytotoxic and IV compounding workflows, particularly relevant for safety-critical chemotherapy preparation.

Regional players

• HPS (Health Provider Services) / RxOne: RxOne is a New Zealand pharmacy management software and services provider supporting community and clinical pharmacies. Regional peer relevant to iMIX given shared NZ healthcare ecosystem and shared customer base of pharmacy and healthcare providers.
• Pharmaco (Pharmaco Australia & NZ): Pharmaco is a New Zealand and Australia-based pharmaceutical and healthcare products distributor and services provider. Regional peer to iMIX given shared market (NZ), overlap with healthcare provider customers, and involvement in specialty pharmaceutical supply.

Direct peers

• Pharmedium (AmerisourceBergen): Pharmedium provides outsourced hospital pharmacy compounding, including sterile preparations and IV admixtures, to US healthcare providers. Highly comparable to iMIX in service category (sterile compounding for hospitals) and operating model (outsourced CIVAS).
• Central Admixture Pharmacy Services (CAPS): CAPS is a leading outsourced provider of sterile admixture and compounding services to hospitals and clinics in the US. Directly comparable to iMIX in CIVAS/IV admixture compounding model, regulatory licensing approach, and B2B healthcare provider customer base.
• Fagron: Fagron is a global leader in pharmaceutical compounding, supplying APIs, bases, and compounding services to pharmacies. Directly comparable to iMIX in personalised compounding and the production of patient-specific medications, though Fagron operates at a much larger scale across multiple geographies.
• Medisca: Medisca supplies pharmaceutical compounding ingredients, equipment, and bases to compounding pharmacies globally. Directly comparable to iMIX in the compounding pharmacy segment, with overlapping customer base of pharmacy compounders.

Emerging players

• HealthCare Logistics: HealthCare Logistics supplies compounding equipment, IV admixture tools, and pharmacy packaging to compounding pharmacies and hospitals. Adjacent peer to iMIX given its role in the compounding pharmacy supply chain and partial overlap in CIVAS/sterile prep workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/imix-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iMIX